Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The BLISS-LN trial

This BLISS-LN trial demonstrated the potential of belimumab as an add-on therapy for patients with lupus nephritis; lead investigator Richard Furie discusses why these findings are important for this patient population (8:28).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

Related content

05-06-2020 | EULAR 2020 | Conference coverage | News

Belimumab shows promise for lupus nephritis

20-06-2018 | Systemic lupus erythematosus | EULAR 2018 | News

Encouraging long-term safety findings for belimumab in SLE
Image Credits